ALPN
Alpine Immune Sciences Inc. · NASDAQ
$64.98+0.02 (+0.03%)today
- Prev close
- $64.97
Alpine Immune Sciences Inc. (ALPN) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for ALPN in the last 30 days. The most recent was published Jan 9, 2025.
Latest news
25 items- PRFrazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture PartnersFrazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointments of Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as Venture Partners. "We believe Mitch and Stanford bring exceptional leadership and experience that will elevate our ability to create and nurture breakthrough biopharmaceutical companies," said Jamie Topper, M.D., Ph.D., Managing Partner at FLS. "Mitch's history of building transformative companies, his relentless pursuit of scientific excellence and his proven ability to identify transformative scientific and investment opportunities make him a valuable addition to our team. Similarly, Stanford's p
- PRAttovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of DirectorsFREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades of industry leadership experience, including early- and late-stage therapeutic development and commercialization. "I am delighted to welcome Mitch and Angie to the team. They are industry leaders with a proven track record of success in building both public and private biopharma companies. As Attovia looks toward our next stage of growth and drives our mission of bringing forward first-in-c
- SECSEC Form 15-12G filed by Alpine Immune Sciences Inc.15-12G - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)
- SECSEC Form EFFECT filed by Alpine Immune Sciences Inc.EFFECT - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)
- SECSEC Form EFFECT filed by Alpine Immune Sciences Inc.EFFECT - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)
- 13D/GSEC Form SC 13D/A filed by Alpine Immune Sciences Inc. (Amendment)SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)
- 13D/GSEC Form SC 13D/A filed by Alpine Immune Sciences Inc. (Amendment)SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)
- INSIDERPeetz Christopher returned 1,900 shares to the company (SEC Form 4)4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
- INSIDERSEC Form 4 filed by Hernday Natasha4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
- INSIDERSEC Form 4 filed by Drappa Jorn4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
- INSIDERConway Robert E returned 50,000 shares to the company (SEC Form 4)4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
- INSIDERSEC Form 4 filed by Topper James N4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
- INSIDERSEC Form 4 filed by Thompson Peter A.4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
- INSIDERSEC Form 4 filed by Cui Xiangmin4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
- INSIDERRickey James Paul returned 57,961 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
- INSIDERPeng Stanford L returned 344,163 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
- INSIDERGold Mitchell returned 109,245 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
- INSIDERFuhs Ulrich Martin returned 30,120 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
- INSIDERDurand Remy returned 133,392 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
- INSIDERSEC Form 4 filed by Orbimed Advisors Llc4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)
- SECSEC Form 25-NSE filed by Alpine Immune Sciences Inc.25-NSE - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)
- SECSEC Form S-8 POS filed by Alpine Immune Sciences Inc.S-8 POS - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)
- SECSEC Form S-8 POS filed by Alpine Immune Sciences Inc.S-8 POS - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)
- SECSEC Form S-8 POS filed by Alpine Immune Sciences Inc.S-8 POS - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)
- SECSEC Form S-8 POS filed by Alpine Immune Sciences Inc.S-8 POS - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)
ALPN FAQ
8 questionsWhat does Alpine Immune Sciences Inc. do?
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated...What is the latest news on ALPN?
Quantisnow has not tracked any new filings, ratings or press releases for ALPN in the last 30 days. The most recent wire item was published on January 9, 2025.Where does ALPN stock trade?
Alpine Immune Sciences Inc. (ALPN) is listed on NASDAQ.What sector and industry is ALPN in?
Alpine Immune Sciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Alpine Immune Sciences Inc. go public?
Alpine Immune Sciences Inc. (ALPN) completed its IPO in 2015.What are analysts saying about ALPN?
Alpine Immune Sciences Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $55.00 price target on 2024-04-09. Recent price targets range from $14.00 to $55.00.What companies are similar to ALPN?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare ALPN side-by-side with any of them on Quantisnow.How can I track ALPN on Quantisnow?
Quantisnow aggregates Alpine Immune Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALPN to receive live email and push alerts on every new disclosure.